Gregory J Dore
Biographic Data
| ID | 5551682 |
|---|---|
| NAME | Gregory J Dore |
| GIVEN NAMES | Gregory J |
| FAMILY NAME | Dore |
| SIGNATURE | DORE G J |
| AFFILIATIONS | UNSW Sydney |
| ORCID | 0000-0002-4741-2622 |
| VERIFIED | Yes |
| TOTAL WORKS | 76 |
| TOTAL CITATIONS | 2 |
| AUTHOR COUNT | 76 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 1997 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia
Large Language Models Accurately Identify People Who Inject Drugs From Infectious Diseases Discharge Summaries in an Australian Hospital
Factors Associated With Preferences for Opioid Agonist Therapies Among People Dependent on Opioids
Interventions to improve testing, linkage to care, and treatment for hepatitis C infection in prison
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons. The finding that reinfection accounts for most recurrent viremia could assist retreatment clinical decision-making in prison
Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia
During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use
The relatively high incidence of reinfection seen in this study underscores the importance of targeted harm reduction measures and monitoring for HCV reinfections within the first year following successful treatment among people who inject drugs. Additional research into integrated models of care incorporating harm reduction and supporting reducing risk of reinfection and HCV treatment are needed
Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey
The temporal decline in HCV Ab prevalence appears related to reduced sensitivity of DBS HCV Ab detection with viral clearance following treatment. Since 2016, HCV treatment uptake has increased markedly including among people who inject drugs. In this context, continuing to monitor HCV Ab prevalence by DBS testing is problematic, with a shift to surveillance of active infection the most relevant to guide policy and practice in this setting
Monitoring hepatitis C elimination among people who inject drugs
Patient preferences for simplified hepatitis C testing modalities among people at risk of hepatitis C infection in Australia
Findings highlight the importance of offering rapid, staff-assisted HCV testing to improve uptake among at-risk populations
Acceptability of hepatitis C testing using point-of-care testing and dried blood spot collection among people at risk of hepatitis C infection
Applying Sekhon's acceptability framework highlighted remaining service gaps to bridge client HCV testing experiences, including enhanced education on testing modalities and their results, an increased need for non-judgemental care, and the use of peer support in community settings
Challenges and facilitators in repeated bio-behavioural surveys for blood-borne virus infections in Australian prisons
The high participation and informative findings indicated clear feasibility of this improved surveillance system. Strong stakeholder engagement and flexibility in logistics facilitated successful implementation of multi-jurisdictional prison-based surveillance
Prevalence and engagement with healthcare services for hepatitis B infection among people in prison in Australia
HBsAg prevalence was low overall, but disproportionately higher among First Nations people and people born overseas. Lower likelihood of HBV in people injecting drugs might be explained by higher chance of spontaneous clearance in adulthood or high-coverage HBV vaccination programs for children and adolescents, and subsequent immunity in many people by the time they start injecting drugs. Prison-based HBV testing uptake and vaccination coverage w…
Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia
Needle and syringe sharing among people who have recently injected drugs in Australia
Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs
Among 2,395 participants enrolled in ETHOS Engage, 66% (n = 1,591) were men, 33% (n = 786) women, and <1% (n = 18) did not identify as a man or woman. HCV testing history and current infection were similar among men and women. Among men or women ever eligible for HCV treatment (ever chronic HCV) (n = 1,242), women were less likely to report a history of HCV treatment compared to men (227/352, 64% vs. 631/890, 71%; p = 0.03). Among women, those ag…
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs
Results highlight important intersections and disparities in stigmatising experiences among people who inject drugs. Considering these intersections can assist health services provide more inclusive care
Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs
A stigma and time framework illuminated multiple overlapping stigmatizing experiences for women who inject drugs in HCV care and in turn, can help to inform tools and interventions to counter their impact
Week Retention in Treatment With Extended-Release Subcutaneous Buprenorphine Depot Injections Among People With Opioid Dependence
Indivior
Vaccination coverage among people who inject drugs
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs
Covid ‐19 vaccine attitudes and facilitators among people in Australia who inject drugs
Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia
Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings
Providing outreach hepatitis C services in community-based services was effective in engaging people living with and at-risk of hepatitis C, in education, testing, and care. Nurse-led, person-centred care was critical to the success of the project. Our evaluation underscores the importance of employing a partnership approach when delivering hepatitis C models of care in community settings, and incorporating workforce education and capacity-buildi…
Health-related quality of life among people who inject drugs in Australia
The study findings provide important HRQoL data for economic evaluations, useful for guiding the allocation of resources for HCV elimination strategies and interventions among PWID
HIV-1 Infection among Female Commercial Sex Workers in Rural Thailand
A retrospective study of 821 commercial sex workers attending a sexually transmitted disease (STD) clinic in northern Thailands Chiang Rai Province from 1989 to 1993 revealed an explosive epidemic of human immunodeficiency virus (HIV). The overall seroprevalence among the 556 women for whom antibody tests were available was 52.3%. However a dramatic increase in HIV-1 seroprevalence occurred from 1989 (29.3%) to 1990 (54.1%) followed by a leveling…
Infant feeding practices and attitudes among women with HIV infection in northern Thailand
Knowledge and attitudes towards infant feeding among women in northern Thailand were examined. Face-to-face interviews using structured questionnaires were undertaken in three districts of Chiang Rai province. Subjects included postnatal women with HIV infection (group 1, n=80), antenatal women with HIV infection (group 2, n=36) and antenatal women with unknown HIV status (group 3, n=86). Advantages of breastfeeding and formula feeding according …
Effectiveness of needle and syringe programmes for preventing HIV transmission
Injecting behaviour of injecting drug users at needle and syringe programmes and pharmacies in Australia
The Effect of Hepatitis C Virus Infection on Health-Related Quality of Life in Prisoners
Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment
Experience of hepatitis C testing among injecting drug users in Sydney, Australia
Testing injecting drug users (IDUs) for HIV and hepatitis C virus (HCV) provides a useful opportunity for health promotion, risk-reduction assessment and counselling, and increases opportunities for treatment assessment, yet little is known about IDUs' experience of testing. This study aimed to examine the experiences of testing among IDUs recruited through primary healthcare and drug treatment services. Almost all the 229 participants recruited …
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort
Hepatitis C virus (HCV) infection is common in prisoner populations, particularly those with a history of injecting drug use (IDU). Previous studies of HCV incidence have been based on small case numbers and have not distinguished risk events in prison from those in the community. HCV incidence was examined in a longitudinal cohort of 488 Australian prisoners with a history of IDU and documented to be seronegative within 12 months prior to enrolm…
Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C
Hospital-related morbidity overall and for non alcoholic liver disease was considerably higher for HCV than HBV. Improved treatment of advanced HBV-related liver disease may explain why HBV liver-related morbidity declined. In contrast, HCV liver-related morbidity increased and improved treatments, especially for advanced liver disease, and higher levels of treatment uptake are required to reverse this trend
Epidemiology and natural history of HCV infection
Hepatitis C virus treatment for prevention among people who inject drugs
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of …
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs
Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting
Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia
Defining populations and injecting parameters among people who inject drugs
Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs
The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug us…
Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs
A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs
BACKGROUND: Hepatitis C virus (HCV) testing and counselling have the potential to impact individual behaviour and transmission dynamics at the population level. Evidence of the impact of an HCV-positive status notification on injection risk reduction is limited. The objective of our study was to (1) assess drug and alcohol use and injection risk behaviours following notification; (2) to compare behaviour change in people who inject drugs (PWID) w…
Global prevalence and genotype distribution of hepatitis C virus infection in 2015
‘I didn’t want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign
Estimating the number of people who inject drugs in Australia
These are the first indirect prevalence estimates of injecting drug use in Australia in over a decade. This work has identified that there are limited data available to inform estimates of this population. These estimates can be used as a basis for further work estimating injecting drug use in Australia
Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia
Medicine (65 works) · Hepatitis C virus research (57 works) · HIV, Drug Use, Sexual Risk (47 works) · Hepatitis C (39 works) · Internal Medicine (36 works) · Hepatitis B Virus Studies (28 works) · Hepatitis C virus (27 works) · Virus (25 works) · Immunology (23 works) · Environmental health (19 works)